MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

Bayer AG

Отворен

СекторФинансови

21.76 1.87

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

20.405

Максимум

21.835

Ключови измерители

By Trading Economics

Приходи

3.9B

-328M

Продажби

1.8B

12B

P/E

Средно за сектора

30.9

22.015

EPS

1.05

Дивидентна доходност

0.49

Марж на печалбата

-2.796

Служители

90,587

EBITDA

615M

1.7B

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+20.47% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.49%

3.90%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

422M

22B

Предишно отваряне

19.89

Предишно затваряне

21.76

Настроения в новините

By Acuity

26%

74%

87 / 542 Класиране в Finance

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Bayer AG Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.03.2025 г., 09:37 ч. UTC

Значими двигатели на пазара

Bayer Shares Plunge After U.S. Court Defeat in Roundup Case -- Update

5.03.2025 г., 11:21 ч. UTC

Печалби

Bayer Warns of Lower Earnings as Turnaround Continues -- 2nd Update

5.03.2025 г., 08:45 ч. UTC

Печалби

Bayer Warns of Lower Earnings as Turnaround Continues -- Update

5.03.2025 г., 07:26 ч. UTC

Печалби

Bayer Warns of Lower Earnings as Work Continues on Turnaround

2.04.2025 г., 09:27 ч. UTC

Горещи акции

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

10.03.2025 г., 08:38 ч. UTC

Пазарно говорене

Bayer's Partial Recovery Is in Sight -- Market Talk

5.03.2025 г., 13:39 ч. UTC

Пазарно говорене
Печалби

Bayer Guidance Is Mostly Above Barclays's Expectations, But Cash Flow Looks Light -- Market Talk

5.03.2025 г., 13:26 ч. UTC

Пазарно говорене

Bayer Investors Will Need Patience Despite Positive Earnings Surprise -- Market Talk

5.03.2025 г., 08:30 ч. UTC

Пазарно говорене
Печалби

Bayer's Cash Flow Guidance Looks Soft -- Market Talk

5.03.2025 г., 06:41 ч. UTC

Печалби

Bayer Launches Plan to Boost Profitability at Crop Science

5.03.2025 г., 06:40 ч. UTC

Печалби

Bayer Sees Tangible Steps Toward U.S. Litigation Containment on Horizon This Year

5.03.2025 г., 06:39 ч. UTC

Печалби

Bayer: Pharmaceuticals Division Projected to Return to Sales Growth From 2027, Expand Margins in 2028

5.03.2025 г., 06:39 ч. UTC

Печалби

Bayer Expects to Increase Combined Sales of Nubeqa and Kerendia From EUR2B to More Than EUR2.5B in 2025

5.03.2025 г., 06:36 ч. UTC

Печалби

Bayer Says 2025 to be Pivotal Year For Turnaround, Improved Performance Expected From 2026

5.03.2025 г., 06:35 ч. UTC

Печалби

Bayer Guidance is on a Currency Adjusted Basis

5.03.2025 г., 06:34 ч. UTC

Печалби

Bayer Sees 2025 Free Cash Flow EUR1.5B-EUR2.5B

5.03.2025 г., 06:34 ч. UTC

Печалби

Bayer Sees 2025 Core EPS EUR4.50-EPS EUR5

5.03.2025 г., 06:33 ч. UTC

Печалби

Bayer Sees 2025 EBITDA Before Special Items of EUR9.5B-EUR10B

5.03.2025 г., 06:33 ч. UTC

Печалби

Bayer Sees 2025 Sales EUR45B-EUR47B

5.03.2025 г., 06:32 ч. UTC

Печалби

Bayer Declares Dividend of EUR0.11 Vs EUR0.11

5.03.2025 г., 06:31 ч. UTC

Печалби

Bayer: Analysts Saw 4Q Net Profit at EUR463M

5.03.2025 г., 06:31 ч. UTC

Печалби

Bayer 4Q Net Loss EUR335M

5.03.2025 г., 06:31 ч. UTC

Печалби

Bayer: Analysts Saw 4Q Ebitda Before Special Items at EUR2.27B

5.03.2025 г., 06:31 ч. UTC

Печалби

Bayer 4Q Ebitda Before Special Items EUR2.35B

5.03.2025 г., 06:31 ч. UTC

Печалби

Bayer: Analysts Saw 4Q Sales at EUR11.26B

5.03.2025 г., 06:31 ч. UTC

Печалби

Bayer 4Q Sales EUR11.73B

13.01.2025 г., 21:05 ч. UTC

Топ новини

Bayer's Head of Pharma Oelrich Expects Business to Return to Growth in 2027

9.01.2025 г., 15:06 ч. UTC

Придобивния, сливания и поглъщания

Bayer Didn't Disclose Financial Details

9.01.2025 г., 15:05 ч. UTC

Придобивния, сливания и поглъщания

Bayer: Goal Is to Help Decarbonize Transportation Sector With Advancing Innovative Crops

9.01.2025 г., 15:05 ч. UTC

Придобивния, сливания и поглъщания

Bayer: Camelina Is Novel Intermediate Oilseed Crop

Сравнение с други в отрасъла

Ценова промяна

Bayer AG Прогноза

Ценова цел

By TipRanks

20.47% нагоре

12-месечна прогноза

Среден 26.89 EUR  20.47%

Висок 33 EUR

Нисък 22 EUR

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Bayer AG през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

10 ratings

1

Купи

9

Задържане

0

Продай

Техническа оценка

By Trading Central

21.95 / 22.575Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

87 / 542 Класиране в Финансови

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.